psychedelics

R&D

Psychedelic treatments on cusp of approval, but questions re...

There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

Cybin bags breakthrough tag for psychedelic depression drug

It has been a busy week for psychedelic medicines developer Cybin, marked by a breakthrough designation (BTD) from the FDA for its depression therapy, new clinical data, a

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

News

MindMed says LSD-based therapy effective in anxiety

Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an

Psychedelic treatments on cusp of approval, but questions re...

Beckley builds case for its psychedelic depression therapy

Cybin bags breakthrough tag for psychedelic depression drug

MindMed gets FDA breakthrough tag for LSD in anxiety

atai invests $50m in Beckley Psytech

MindMed says LSD-based therapy effective in anxiety

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

psychedelics

Editor's Picks